May 16, 2024 7:00 am EDT Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
May 14, 2024 7:00 am EDT Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
Apr 16, 2024 7:00 am EDT Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Feb 13, 2024 4:30 pm EST Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Jan 18, 2024 5:00 pm EST Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
Jan 4, 2024 4:45 pm EST Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
